[{"data":1,"prerenderedAt":136},["ShallowReactive",2],{"naujienos/your-next-biotechnology-partner-might-be-from-the-baltics/en":3},{"status":4,"data":5},true,{"image":6,"id":14,"seo":15,"title":12,"date":90,"url":86,"fullUrl":26,"text":91,"excerpt":92,"more":93,"tags":134,"temos":135},{"src":7,"is_svg":8,"ratio":9,"width":10,"height":11,"alt":12,"caption":13},"https://web-prod.inovacijuagentura.lt/wp-content/uploads/2024/08/biotech-paveiksliukas-3840x2561.jpg",false,0.6669270833333333,3840,2561,"Your next biotechnology partner might be from the Baltics","",6931,{"title":16,"robots":17,"og_locale":23,"og_type":24,"og_title":16,"og_description":25,"og_url":26,"og_site_name":27,"article_publisher":28,"og_image":29,"twitter_card":34,"schema":35,"breadcrumbs":78,"description":13,"language":87},"Your next biotechnology partner might be from the Baltics - Inovacijų agentūra",{"index":18,"follow":19,"max-snippet":20,"max-image-preview":21,"max-video-preview":22},"index","follow","max-snippet:-1","max-image-preview:large","max-video-preview:-1","en_US","article","In recent years, a growing biotechnology hub in Europe, Lithuania, has emerged as a tough player in the global biotechnology arena. A country known for its robust educational system and scientific innovations now exports 95% of its life sciences production globally with almost 30% landing in the United States, a market known for its advanced R&D.","https://www.inovacijuagentura.lt/en/naujiena/your-next-biotechnology-partner-might-be-from-the-baltics/","Inovacijų agentūra","https://www.facebook.com/inovacijuagentura",[30],{"width":31,"height":32,"url":7,"type":33},"7952","5304","image/jpeg","summary_large_image",{"@context":36,"@graph":37},"https://schema.org",[38,53,55,65,69],{"@type":39,"@id":26,"url":26,"name":16,"isPartOf":40,"primaryImageOfPage":42,"image":44,"thumbnailUrl":7,"datePublished":45,"breadcrumb":46,"inLanguage":48,"potentialAction":49},"WebPage",{"@id":41},"https://www.inovacijuagentura.lt/en/#website",{"@id":43},"https://www.inovacijuagentura.lt/en/naujiena/your-next-biotechnology-partner-might-be-from-the-baltics/#primaryimage",{"@id":43},"2024-08-01T05:21:00+00:00",{"@id":47},"https://www.inovacijuagentura.lt/en/naujiena/your-next-biotechnology-partner-might-be-from-the-baltics/#breadcrumb","en-US",[50],{"@type":51,"target":52},"ReadAction",[26],{"@type":54,"inLanguage":48,"@id":43,"url":7,"contentUrl":7,"width":31,"height":32,"caption":12},"ImageObject",{"@type":56,"@id":47,"itemListElement":57},"BreadcrumbList",[58,63],{"@type":59,"position":60,"name":61,"item":62},"ListItem","1","Home","https://www.inovacijuagentura.lt/en/",{"@type":59,"position":64,"name":12},"2",{"@type":66,"@id":41,"url":62,"name":27,"description":13,"publisher":67,"inLanguage":48},"WebSite",{"@id":68},"https://www.inovacijuagentura.lt/en/#organization",{"@type":70,"@id":68,"name":27,"url":62,"logo":71,"image":76,"sameAs":77},"Organization",{"@type":54,"inLanguage":48,"@id":72,"url":73,"contentUrl":73,"width":74,"height":75,"caption":27},"https://www.inovacijuagentura.lt/en/#/schema/logo/image/","https://web-prod.inovacijuagentura.lt/wp-content/uploads/2026/05/ia-logo-main.svg","1886","786",{"@id":72},[28],[79,82,85],{"url":80,"text":61,"id":81},"/en/",7576,{"url":83,"text":84},"/en/news/","News",{"url":86,"text":12,"id":14},"/en/naujiena/your-next-biotechnology-partner-might-be-from-the-baltics/",[88],{"url":26,"code":89,"locale":89,"default":8},"en","2024-08-01","\u003Cp style=\"text-align:justify\">\u003Cstrong>\u003Cspan style=\"color:black\">Europe's Emerging Biotech Hub\u003C/span>\u003C/strong>\u003C/p>\n\u003Cp style=\"text-align:justify\">\u003Cspan style=\"color:black\">With its staggering 11-fold increase of revenue over the decade,\u003Cstrong> \u003C/strong>Lithuania's biotechnology sector is rapidly gaining recognition for its diverse pool of life sciences solutions. \u003C/span>\u003C/p>\n\u003Cp style=\"text-align:justify\">\u003Cspan style=\"color:black\">“There are around 3000 researchers and scientists working in biotech, spanning innovations in such fields as CDMO, microfluidics, clinical trials, medical devices, gene editing-CRISPR technology and gene therapy, blue/marine biotechnologies, protein design, and AI-based medical solutions. The Lithuanian government has also played and still plays a vital role, fostering a conducive environment for biotech innovation through strategic investments and supportive policies,” says Karolis Karalevičius, Business Community Manager at InnoHub Lithuania.\u003C/span>\u003C/p>\n\u003Cp style=\"text-align:justify\">\u003Cspan style=\"color:black\">Recently, InnoHub Lithuania, a division by the non-profit Lithuanian governmental agency Innovation Agency Lithuania, was opened to facilitate the integration between Lithuanian and the US innovation ecosystems, seeking to provide visibility to the most innovative Lithuanian entrepreneurs, connecting them to the local ecosystem and other needed resources in the US. Last month, InnoHub organized an event in San Diego where 10 Lithuanian companies pitched their ideas to US based Lithuanians working in biotech sector.\u003C/span>   \u003C/p>\n\u003Cp style=\"text-align:justify\">\u003Cspan style=\"color:black\">“While the achievements of Lithuanian biotech companies are noteworthy and can be of much use for the US companies, entering such a market is not without challenges. Navigating the regulatory landscape, securing funding, finding partners and clientele, and maintaining competitive advantage is complex. Meeting these needs, InnoHub Lithuania boasts competent local experts and mentors to help Lithuanian biotech navigate locally, and aims to be the local spot for US biotech companies, in need of reliable Lithuanian partners,” adds Karalevičius.\u003C/span>\u003C/p>\n\u003Cp style=\"text-align:justify\">\u003Cspan style=\"color:black\">The Lithuanian biotechnology industry is anchored by several key players whose products and services are gaining awareness in the US. These companies are not only advancing scientific research but also enhancing the quality of healthcare through their innovative solutions:\u003C/span>\u003C/p>\n\u003Cp style=\"text-align:justify\">\u003Cstrong>\u003Cspan style=\"background-color:white\">\u003Cspan style=\"color:black\">Atrandi Biosciences \u003C/span>\u003C/span>\u003C/strong>\u003Cspan style=\"background-color:white\">\u003Cspan style=\"color:black\">specializes in microfluidic technologies that enhance single-cell analysis and high-throughput screening. Their products, such as the ONYX droplet generator and STYX HTS platform, simplify complex workflows by combining droplet generation, manipulation, and sorting with fluorescence analysis. Their Semi-Permeable Capsules (SPCs) support multi-step molecular analysis, maintaining single-cell compartmentalization under various conditions. Atrandi's solutions are trusted by laboratories worldwide, including Thermo Fisher Scientific, accelerating research in molecular biology and diagnostics.\u003C/span>\u003C/span>\u003C/p>\n\u003Cp style=\"text-align:justify\">\u003Cstrong>\u003Cspan style=\"color:black\">Biomatter Designs \u003C/span>\u003C/strong>\u003Cspan style=\"color:black\">is a \u003Cspan style=\"background-color:white\">synthetic biology company that creates new proteins for health and sustainable manufacturing applications. The company has created the Intelligent Architecture™ platform, which addresses the limitations of current engineering approaches to unlock completely new horizons for protein design and development.\u003C/span>\u003C/span>\u003C/p>\n\u003Cp style=\"text-align:justify\">\u003Cstrong>\u003Cspan style=\"background-color:white\">\u003Cspan style=\"color:black\">Caszyme\u003C/span>\u003C/span>\u003C/strong>\u003Cspan style=\"background-color:white\">\u003Cspan style=\"color:black\"> is an innovative company specializing in CRISPR technology. They develop advanced CRISPR-based solutions for therapeutics, agriculture, diagnostics, research and industrial biotechnology. With strong collaborations worldwide, Caszyme leverages its expertise to create customized, market-ready products.\u003C/span>\u003C/span>\u003C/p>\n\u003Cp style=\"text-align:justify\">\u003Cstrong>\u003Cspan style=\"background-color:white\">\u003Cspan style=\"color:black\">Cureline Baltic\u003C/span>\u003C/span>\u003C/strong>\u003Cspan style=\"background-color:white\">\u003Cspan style=\"color:black\"> is a preclinical and translational research Contract Research Organization (CRO) based in Vilnius, Lithuania. It specializes in human biospecimen procurement, preclinical animal research, and laboratory services, focusing on oncology, immunology, and infectious diseases. As part of the global Cureline Group, they serve clients in both the US and European markets, providing essential support for drug and diagnostics development.\u003C/span>\u003C/span>\u003C/p>\n\u003Cp style=\"text-align:justify\">\u003Cstrong>\u003Cspan style=\"background-color:white\">\u003Cspan style=\"color:black\">Memel Biotech,\u003C/span>\u003C/span>\u003C/strong>\u003Cspan style=\"background-color:white\">\u003Cspan style=\"color:black\"> based in Klaipėda, Lithuania, specializes in Contract Development and Manufacturing Organization (CDMO) services for Advanced Therapy Medicinal Products (ATMPs)​. The company offers GMP-compliant facilities and comprehensive services, including precision medicine research, drug development, and regulatory support​. Its strategic location serves as an EU gateway, facilitating collaborations between different markets, bolstered by partnerships like the one with THERABEST Korea​. Memel Biotech's integration with the US-based Cureline Group further enhances its global reach and expertise​.\u003C/span>\u003C/span>\u003C/p>\n\u003Cp style=\"text-align:justify\">\u003Cstrong>\u003Cspan style=\"color:black\">Northway Biotech\u003C/span>\u003C/strong>\u003Cspan style=\"color:black\">, another prominent CDMO, specializes in developing and manufacturing biopharmaceuticals. The company’s focus on monoclonal antibodies and recombinant proteins has positioned it as a valuable partner for US biotech firms seeking innovative therapies. Northway Biotech’s commitment to quality and regulatory compliance has earned it a strong reputation, enabling it to secure partnerships with leading US companies. In 2021, Northway Biotech opened its 30,000-square-foot process development and cGMP manufacturing site in Waltham, Massachusetts to support the market with microbial and mammalian cell culture-based products for the development of monoclonal antibodies and recombinant proteins.\u003C/span>\u003C/p>\n\u003Cp style=\"text-align:justify\">\u003Cstrong>\u003Cspan style=\"background-color:white\">\u003Cspan style=\"color:black\">Spike\u003C/span>\u003C/span>\u003C/strong>\u003Cspan style=\"background-color:white\">\u003Cspan style=\"color:black\"> provides a unified API for accessing real-time health data from over 300 wearable devices and IoT products. Its platform simplifies integration for developers by offering well-documented, easy-to-implement APIs and SDKs, allowing quick testing and development. Spike enhances applications by delivering personalized insights and increasing user retention through standardized, normalized data. Recently, the Lithuanian B2B healthtech data tech startup as announced the successful close of an €3.2 million oversubscribed seed round, co-led by Practica Capital and TheVentureCity with participation from Silicon Valley, New York, and other investors.\u003C/span>\u003C/span>\u003C/p>\n\u003Cp style=\"text-align:justify\">\u003Cstrong>\u003Cspan style=\"color:black\">Thermo Fisher Scientific Baltics\u003C/span>\u003C/strong>\u003Cspan style=\"color:black\">, a subsidiary of the global giant Thermo Fisher Scientific, is a cornerstone of Lithuania’s biotech landscape. Specializing in developing and producing molecular biology products, the Lithuanian branch provides high-quality reagents and instruments to researchers across the US. Their contributions have been particularly significant in genetic research and diagnostics, where top-tier research institutions and pharmaceutical companies utilize their products. In fact, \u003Cstrong>\u003Cspan style=\"background-color:white\">Fermentas, \u003C/span>\u003C/strong>\u003Cspan style=\"background-color:white\">a well-known Lithuanian biotechnology company specializing in discovering and producing molecular biology products for life science research and diagnostics, has been a part of Thermo Fisher Scientific Baltics Since 2010.\u003C/span>\u003C/span>\u003C/p>\n","In recent years, a growing biotechnology hub in Europe, Lithuania,  has emerged as a tough player in the global biotechnology arena. A country known for its robust educational system and scientific innovations now exports 95% of its life sciences production globally with almost 30% landing in the United States, a market known for its advanced R&D.",[94,103,112,126],{"image":95,"title":98,"url":99,"id":100,"text":101,"temos":102},{"src":96,"is_svg":8,"ratio":97,"alt":98,"caption":13},"https://web-prod.inovacijuagentura.lt/wp-content/uploads/2026/05/kosmoso-memorandumas-su-polsa.jpg",0.6669921875,"Lithuania Strengthens Cooperation with Poland and the United States in the Space Sector: Important Memorandums Signed","/en/naujiena/lithuania-strengthens-cooperation-with-poland-and-the-united-states-in-the-space-sector-important-memorandums-signed/",6748,"Lithuania’s space sector continues to strengthen international partnerships and expand cooperation with key players in the global space industry. Innovation Agency Lithuania has recently signed two significant memorandums of understanding – with the Polish Space Agency (POLSA) and the U.S. space infrastructure company Vast. These agreements open new opportunities for Lithuanian businesses, research institutions, and international projects.",[],{"image":104,"title":107,"url":108,"id":109,"text":110,"temos":111},{"src":105,"is_svg":8,"ratio":106,"alt":107,"caption":13},"https://web-prod.inovacijuagentura.lt/wp-content/uploads/2026/03/shutterstock-2539768243-1.jpg",0.7490234375,"Lithuania Ranks First in Europe in the Global Entrepreneurship Index","/en/naujiena/lithuania-ranks-first-in-europe-in-the-global-entrepreneurship-index/",6892,"The latest Global Entrepreneurship Monitor (GEM) 2025/2026 global report shows that Lithuania is the leading country in Europe in terms of the quality of its entrepreneurial environment and ranks among the world’s strongest economies in this field.",[],{"image":113,"title":115,"url":116,"id":117,"text":118,"temos":119},{"src":114,"is_svg":8,"ratio":97,"alt":115,"caption":13},"https://web-prod.inovacijuagentura.lt/wp-content/uploads/2026/01/karolina-urbonaite.jpg","Lithuania’s Startup Ecosystem Surpasses €16.4 Billion in Value: Investments Jump 1.7x in 2025","/en/naujiena/lithuanias-startup-ecosystem-surpasses-e16-4-billion-in-value-investments-jump-1-7x-in-2025/",6999,"The total value of Lithuania’s startup ecosystem reached €16.4 billion in 2025, according to the latest Dealroom report initiated by Startup Lithuania, a division of the Innovation Agency. In just one year, Lithuanian startups attracted €220 million in venture capital investments from 77 unique investors. The ecosystem’s growing maturity was further confirmed earlier this year with the addition of a new unicorn to Lithuania’s startup map — Cast AI.",[120,123],{"id":121,"name":122},577,"Growth",{"id":124,"name":125},579,"Innovation",{"image":127,"title":129,"url":130,"id":131,"text":132,"temos":133},{"src":128,"is_svg":8,"ratio":97,"alt":129,"caption":13},"https://web-prod.inovacijuagentura.lt/wp-content/uploads/2025/12/modix-fgf-3d-spausdintuvas-2.jpg","Mission-Driven Innovations: Science and Business Shaping Lithuania’s Future","/en/naujiena/mission-driven-innovations-science-and-business-shaping-lithuanias-future/",6904,"Some important scientific research activities and innovative business-developed products may sound complex – unsurprisingly, as they are developed by people who dedicate their entire lives to these fields. Yet behind these sophisticated terms lie concrete solutions that will eventually make each of our daily lives easier. Where science and business join forces, more accurate disease diagnostics for the health of us and our loved ones are developed, cybersecurity tools are created to protect the country, and climate-neutral production technologies and materials emerge to help preserve our nature and resources.",[],[],[],1780347788397]